NCT00724295View on ClinicalTrials.gov

Safety and Efficacy of PegIntron and Rebetol Combination Therapy in Patients With Chronic Hepatitis C in Japan (Study P04505)

CompletedOBSERVATIONAL

Enrollment

1,077

Participants

Timeline

Start Date

April 30, 2005

Primary Completion Date

December 31, 2008

Study Completion Date

December 31, 2008

Conditions

Hepatitis C, ChronicHepatitis C

Interventions

DRUG

peginterferon alfa-2b

PegIntron powder (reconstituted) administered in accordance with approved labeling; Subcutaneous injection of 1.5 ug/kg once weekly for 48 weeks.

DRUG

ribavirin

Rebetol capsule administered orally twice daily in accordance with approved labeling (weight based dosing). Dosing duration 48 weeks.

All Listed Sponsors

lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00724295 - Safety and Efficacy of PegIntron and Rebetol Combination Therapy in Patients With Chronic Hepatitis C in Japan (Study P04505) | Biotech Hunter | Biotech Hunter